Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

avagacestat

Known as: (2R)-2-(N-((4-Chlorophenyl)sulfonyl)-N-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoropentanamide, Pentanamide, 2-(((4-chlorophenyl)sulfonyl)((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)amino)-5,5,5-trifluoro-, (2R)- 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

BMS 708163

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
IMPORTANCE Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to… Expand
Is this relevant?
2015
2015
The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis
Hepatic stellate cells (HSCs) known as "master producers" and macrophages as "master regulators", are the key cell types that… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches.
WHAT IS KNOWN AND OBJECTIVE The prevailing theory regarding Alzheimer disease (AD) is that insoluble amyloid β-peptide (Aβ) plays… Expand
Is this relevant?
2013
2013
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
A hallmark of Alzheimer’s disease (AD) pathology is the accumulation of brain amyloid β-peptide (Aβ), generated by γ-secretase… Expand
  • table 1
Is this relevant?
2013
2013
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
AIM To evaluate the single dose pharmacokinetics, pharmacodynamics, and preliminary tolerability of the γ-secretase inhibitor BMS… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
OBJECTIVE To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters…
BACKGROUND γ-Secretase inhibitors (GSIs) are being investigated for their potential to modify the progression of Alzheimer… Expand
Is this relevant?
2012
2012
A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
Background and ObjectivesAvagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men
BackgroundThe concentration of amyloid β (Aβ) peptides in cerebrospinal fluid (CSF) is a biomarker for Alzheimer’s disease (AD… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
BMS-708,163 targets presenilin and lacks notch-sparing activity.
The "Notch-sparing" γ-secretase inhibitor (GSI) BMS-708,163 (Avagacestat) is currently in phase II clinical trials for Alzheimer… Expand
  • figure 1
  • table 1
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE